Viyada Sarabanchong, MD

Education

Bachelor’s Degree – Brown University

Medical Degree – Columbia University

Internship – Columbia Presbyterian Medical Center

Residency – Columbia Presbyterian Medical Center

Fellowship – Columbia Presbyterian Medical Center

Board Certifications – Gastroenterology, Internal Medicine

Effects of Increasing Interferon Alopha-2b Dose in Patients with Chrnoic Hepatitis C Not Responding to 3 Million Units 3 Times a Week.
Delariva E, Puppo MD, Factor SH, Sarabanchong V, Ligresti RJ, Finegold J, Riley TH, Garcia-Carrasquillo RJ, Markowitz DD, Magun AM, Worman HJ.
Hepatology, 26 (4); p. 417 A (abstract) November 1997
Interferon-a-2b and Ribavirin for Retreatrnent of Chronic Hepatitis C.
Dettmer R, Reinus JF, Clain DJ, Aytaman A, Levendoglu H, Bloom AA, Isaacson MP, Spinnell M, Meyer D, Sarabanchong V, Zhang Y, Garcia-Carrasquillo RJ, Markowitz DD, Magun AM, Worman HJ. Hepato-Gastroenterology 2002; 49:758-763
April 2003 -Abbott Laboratories: A Multi-Center, Randomized, Double-Blind, Placebo Controlled Study of Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects with Crohn’s Disease.
September 2003 -GlaxoSmithKline -A 12-Week, Randomized, Double-Blind, PlaceboControlled Study of PRN BID and Fixed Dosing Regimens of Alosetron in Female Subjects with Severe Diarrhea-Predominant Irritable Bowel Syndrome Who Have Failed Conventional Therapy.